Status:
UNKNOWN
Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Gastric Cancer
Chemoradiation
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Gastric cancer is one of the most common malignant tumors in China, and the incidence and mortality rate are second in malignant tumors. The treatment of gastric cancer need integrated multidisciplina...
Detailed Description
After enrolled in this study, the patient was first treated with radiotherapy, concurrent with oral S-1 80mg/m2/day, on radiotherapy days. 3 weeks after the end of radiotherapy, patients treated with ...
Eligibility Criteria
Inclusion
- Clinical stage T3-4N+M0
- Gastric cancer or Siewert II/III esophagogastric junction carcinoma;
- Pathologically confirmed adenocarcinoma;
- 18-75 years old, male or female;
- Karnofsky score \>= 70;
- White blood cell count \>= 4 x 109 / L; platelet count \>= 100 x109/L; serum creatinine =\< 1 x upper limit of normal, total bilirubin =\< 1 x upper limit of normal, alanine aminotransferase and aspartate aminotransferase =\< 2.5 x upper limit of normal, alkaline phosphatase =\< 5 x upper limit of normal.
Exclusion
- Any chemotherapy or radiotherapy history before enrollment
- Siewert I EGJ cancer
Key Trial Info
Start Date :
May 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03427684
Start Date
May 1 2016
End Date
December 31 2020
Last Update
February 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital, Chinese academy of medical sciences
Beijing, Beijing Municipality, China, 100021